Review
Medicine, Research & Experimental
Omotola D. Ogundipe, Oluwabukunmi Olajubutu, Simeon K. Adesina
Summary: Ovarian cancer is a deadly disease, with most patients diagnosed in advanced stages. Targeted drug conjugate systems offer a promising treatment strategy.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Review
Oncology
Rossella Reddavid, Simona Dagatti, Caterina Franco, Lucia Puca, Mariano Tomatis, Simona Corso, Silvia Giordano, Maurizio Degiuli
Summary: Despite the addition of molecular therapy in the clinical treatment of advanced and metastatic gastric cancer, the survival benefits of these novel therapies remain rather unclear, possibly due to inaccurate patient selection.
Editorial Material
Oncology
Rachel N. N. Grisham, Beryl L. L. Manning-Geist, M. Herman Chui
Summary: Estrogen receptor immunohistochemistry is not reliable for assessing response to antihormonal therapy; further research is needed for prognostic value of progesterone receptor immunohistochemistry. Multigene assays have the potential to serve as a diagnostic tool to identify patients who are less likely to respond to single-agent endocrine therapy and determine optimal combination strategies.
Article
Nanoscience & Nanotechnology
Mahaveer P. Purohit, Aditya K. Kar, Manisha Kumari, Debabrata Ghosh, Satyakam Patnaik
Summary: Combining antiangiogenic and chemotherapeutic drugs within multimodal nanocarriers has shown promising clinical benefits in inhibiting tumor growth and progression. The study reports the combinatorial efficacy of heparin, selenium NPs, and doxorubicin in inhibiting cancer cell viability and inducing apoptosis. The nanocarriers demonstrated excellent water dispersity and strong anticancer potential in in vitro assays, while in vivo imaging highlighted their tumor targeting ability. Overall, these results qualify the nanocarriers as a potential clinical therapeutic candidate.
ACS APPLIED MATERIALS & INTERFACES
(2023)
Article
Multidisciplinary Sciences
Joonas Jukonen, Lidia Moyano-Galceran, Katrin Hopfner, Elina A. Pietila, Laura Lehtinen, Kaisa Huhtinen, Erika Gucciardo, Johanna Hynninen, Sakari Hietanen, Seija Grenman, Paivi M. Ojala, Olli Carpen, Kaisa Lehti
Summary: The study indicates that ephrinA5 is specifically overexpressed in the most aggressive high-grade serous carcinoma and correlates with poor overall survival in patients. On the other hand, high expression of EFNA3 may predict improved overall and progression-free survival in cancer patients.
SCIENTIFIC REPORTS
(2021)
Article
Immunology
Hongling Peng, Xiang He, Qiao Wang
Summary: Immunotherapies have limited benefits in treating ovarian cancer, mainly due to the immunosuppressive tumor microenvironment. Targeting the tumor microenvironment involves strategies such as eliminating immunosuppressive cells, transforming their activity, or inhibiting their production of immunosuppressive or pro-tumor substances. Drug delivery systems, particularly nanoparticles and liposomes, hold promise for controlled release and targeted delivery, leading to increased efficacy and reduced toxicity compared to free agents.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Weihao Zhang, Kai Zhang, Changfu Liu, Wei Gao, Tongguo Si, Qiang Zou, Zhi Guo, Xueling Yang, Mei Li, Dongming Liu, Han Mu, Huikai Li, Haipeng Yu, Wenge Xing
Summary: This study evaluates the clinical efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with molecular targeted therapy and immunotherapy in patients with primary unresectable hepatocellular carcinoma (uHCC). The results show that the combination therapy significantly improves progression-free survival and patients who undergo successful conversion surgery have better overall survival. Adverse events are common but manageable.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Nanoscience & Nanotechnology
Jiawen Zhao, Liang Zhang, Yingjie Qi, Kui Liao, Zhigang Wang, Ming Wen, Di Zhou
Summary: The study successfully developed multifunctional nanoparticles with targeted therapeutic and diagnostic imaging capabilities for combination therapy of ovarian cancer. These nanoparticles showed excellent dispersity, stability, and optical properties, with a combination of photothermal conversion and chemotherapy achieving highly efficient therapy both in vitro and in vivo. The nanoparticles have the potential for therapeutic guidance and monitoring, with outstanding imaging capabilities for both photoacoustic and X-ray computed tomography imaging.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2021)
Review
Oncology
Tadahiro Shoji, Shunsuke Tatsuki, Marina Abe, Hidetoshi Tomabechi, Eriko Takatori, Yoshitaka Kaido, Takayuki Nagasawa, Masahiro Kagabu, Tsukasa Baba, Hiroaki Itamochi
Summary: Ovarian clear cell and mucinous carcinomas show lower sensitivity to chemotherapy, leading to a poor prognosis. Recent focus has shifted to molecular target drugs and immune checkpoint inhibitors for treatment, with many clinical studies planned. Challenges include finding the best treatment combinations, identifying patients who will benefit from each therapy, and integrating results into standard care for these carcinomas.
Article
Pharmacology & Pharmacy
Ya-Nan Li, Xiaoju Shi, Dandan Sun, Shulan Han, Yifang Zou, Lingzhi Wang, Leilei Yang, Yutong Li, Ying Shi, Jianfeng Guo, Caitriona M. O'Driscoll
Summary: In this study, the potential of melarsoprol (MEL) for hepatocellular carcinoma (HCC) therapy was investigated for the first time using in vitro and in vivo experimental approaches. A folate-targeted polyethylene glycol-modified amphiphilic cyclodextrin nanoparticle was developed for safe, efficient and specific delivery of MEL. The targeted nanoformulation achieved cell-specific uptake, cytotoxicity, apoptosis and migration inhibition in HCC cells, and significantly prolonged the survival of mice with orthotopic tumor without causing toxicity.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Article
Chemistry, Multidisciplinary
Jong Won Lee, Jiwon Choi, Yeonho Choi, Kwangmeyung Kim, Yoosoo Yang, Sun Hwa Kim, Hong Yeol Yoon, Ick Chan Kwon
Summary: RNA interference (RNAi) is a cellular mechanism that regulates gene expression, with small interfering RNA molecules (siRNA) mediating mRNA degradation. Despite the promising therapeutic potential of RNAi technology for diseases like cancer, challenges such as biological instability and limited delivery efficiency remain. Recent advancements in siRNA delivery strategies using cationic lipids and polymers have shown improved pharmacokinetics and delivery efficiency.
JOURNAL OF CONTROLLED RELEASE
(2022)
Article
Biochemistry & Molecular Biology
Santosh K. K. Dasari, Robiya Joseph, Sujanitha Umamaheswaran, Lingegowda S. S. Mangala, Emine Bayraktar, Cristian Rodriguez-Aguayo, Yutuan Wu, Nghi Nguyen, Reid T. T. Powell, Mary Sobieski, Yuan Liu, Mamur A. A. Chowdhury, Paola Amero, Clifford Stephan, Gabriel Lopez-Berestein, Shannon N. N. Westin, Anil K. K. Sood
Summary: EphA2 tyrosine kinase is upregulated in many cancers and correlated with poor patient survival. A chemical screen identified Wee1 kinase inhibitor as a synergistic partner to EphA2-targeted therapeutics. Combination treatment showed enhanced anti-tumor response in endometrial cancer, suggesting the potential of Wee1 inhibition in improving EphA2-targeted therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Nan Jiang, Binyan Zhong, Jintao Huang, Wanci Li, Shuai Zhang, Xiaoli Zhu, Caifang Ni, Jian Shen
Summary: This study retrospectively evaluated and compared the efficacy and safety of transarterial chemoembolization (TACE) combined with molecularly targeted agents plus immune checkpoint inhibitors (TACE+T+I) and TACE combined with molecularly targeted agents (TACE+T) for unresectable hepatocellular carcinoma (uHCC). The results showed that patients in the TACE+T+I group had significantly longer overall survival (OS) and progression-free survival (PFS) compared to the TACE+T group, with manageable toxicities. Therefore, triple therapy with TACE+T+I could improve survival and tumor response in patients with unresectable HCC, compared to TACE+T.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Jocelyn C. Reader, Cong Fan, Eleanor Claire-Higgins Ory, Julia Ju, Rachel Lee, Michele I. Vitolo, Paige Smith, Sulan Wu, Mc Millan Nicol Ching, Emmanuel B. Asiedu, Christopher M. Jewell, Gautam G. Rao, Amy Fulton, Tonya J. Webb, Peixin Yang, Alessandro D. Santin, Huang-Chiao Huang, Stuart S. Martin, Dana M. Roque
Summary: Ovarian cancer can spread within the peritoneal cavity through exfoliation of malignant cells into ascites. Microtentacles (McTNs) are microtubule-based protrusions that may influence the metastatic potential and chemoresistance profile of free-floating cells. This study highlights the importance of McTNs as a therapeutic target for ovarian cancer and suggests that understanding their biology could lead to improved treatments.
Article
Multidisciplinary Sciences
Lucy Wang, James C. C. Evans, Lubabah Ahmed, Christine Allen
Summary: Combination chemotherapy is an established approach to manage toxicities and enhance therapeutic response. Delivery of drug combinations at specific molar ratios achieves synergistic effects with minimized adverse reactions. This study demonstrates the synergistic potential of niraparib and doxorubicin for ovarian cancer treatment, and describes the formulation of a nanoparticle encapsulating the synergistic combination for targeted delivery to ovarian cancer cells.
SCIENTIFIC REPORTS
(2023)